How to Avoid Getting "Tyked" Off When Learning About New JAK Inhibitors In Psoriasis
Oct 28, 2021•12 min•Season 1Ep. 13
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Live from The Wynn Hotel and Casino in Las Vegas, NV, episode 13 of Derms and Conditions, has our host James Q. Del Rosso, DO speaking with Bruce Strober, MD in person at the 2021 Fall Clinical Dermatology Conference. First Dr. Strober discusses older biologic agents in psoriasis and how JAK inhibitors offer improved efficacy while not compromising on safety.
Dr. Strober further discusses in depth how certain JAK inhibitors interact with TYK2 and what he thinks are the most important points regarding this pathway in psoriasis pathophysiology. Finally, Dr. Strober discusses in detail why allosteric binding offers improved specificity in JAK inhibition.
For the best experience, listen in Metacast app for iOS or Android